The estimated Net Worth of Susan Rodriguez is at least 3.54 百万$ dollars as of 21 May 2024. Ms Rodriguez owns over 6,703 units of Ardelyx Inc stock worth over 2,676,588$ and over the last 4 years she sold ARDX stock worth over 274,686$. In addition, she makes 588,961$ as Chief Commercial Officer at Ardelyx Inc.
Ms has made over 16 trades of the Ardelyx Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 6,703 units of ARDX stock worth 52,350$ on 21 May 2024.
The largest trade she's ever made was selling 43,920 units of Ardelyx Inc stock on 6 June 2022 worth over 28,548$. On average, Ms trades about 3,830 units every 52 days since 2020. As of 21 May 2024 she still owns at least 449,092 units of Ardelyx Inc stock.
You can see the complete history of Ms Rodriguez stock trades at the bottom of the page.
Susan Rodriguez is the Chief Commercial Officer at Ardelyx Inc.
As the Chief Commercial Officer of Ardelyx Inc, the total compensation of Ms Rodriguez at Ardelyx Inc is 588,961$. There are 4 executives at Ardelyx Inc getting paid more, with Michael Raab having the highest compensation of 1,728,920$.
Ms Rodriguez is 57, she's been the Chief Commercial Officer of Ardelyx Inc since . There are 6 older and 11 younger executives at Ardelyx Inc. The oldest executive at Ardelyx Inc is Gordon Ringold, 69, who is the Independent Director.
Susan's mailing address filed with the SEC is 222 MERCHANDISE MART, SUITE 2024, CHICAGO, IL, 60654.
Over the last 10 years, insiders at Ardelyx Inc have traded over 37,312,621$ worth of Ardelyx Inc stock and bought 85,247,838 units worth 820,614,871$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of 1,784,764$. The most recent stock trade was executed by Michael Raab on 27 August 2024, trading 7,500 units of ARDX stock currently worth 46,650$.
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Ardelyx Inc executives and other stock owners filed with the SEC include: